- Telo Genomics Corp. (TELO) has completed the laboratory processing and analysis of patient samples related to its multiple myeloma drug-resistance clinical study
- The Mayo Clinic provided the patient samples as part of an ongoing collaboration to evaluate the company’s prognostic technology for multiple myeloma (MM)
- Telo’s study results have been submitted back to the Mayo Clinic for review and analysis
- MM is a challenging and potentially deadly blood cancer that affects plasma cells
- Telo Genomics Corp. is a biotech company
- Telo Genomics Corp. was up 5.00 per cent, trading at $0.315 at 11:01 AM ET
Telo Genomics (TELO) has completed the laboratory processing and analysis of patient samples related to its multiple myeloma drug-resistance clinical study.
The Mayo Clinic provided the patient samples as part of an ongoing collaboration to evaluate the company’s prognostic technology for multiple myeloma (MM).
Telo’s study results have now been submitted back to the Mayo Clinic for review and analysis.
This is the second study being carried out in collaboration with the Mayo Clinic to evaluate the company’s prognostic technology to address multiple unmet clinical needs across the spectrum of MM.
Telo’s ongoing collaboration with the Mayo Clinic includes clinical studies in developing prognostic tools to address two specific unmet clinical needs in managing MM.
The first need is to assess the risk of precursor smouldering myeloma (SMM) patients who may benefit from either immediate intervention for high-risk SMM or active continual monitoring for stable SMM.
The second is identifying MM patients who will develop resistance to first-line treatment within two years and may benefit from an alternative treatment regimen.
In July 2022, Telo announced the completion of processing the patient samples related to its lead product for SMM patients.
MM is a challenging and potentially deadly blood cancer that affects plasma cells, a type of blood cell that helps to fight infection.
“The completion of processing of these two successive cohorts of MM patient samples highlights Telo’s team’s increased efficiency and readiness to scale up to commercial laboratory productivity and bringing the TeloView technology to the market,” stated Sherif Louis, Telo’s CEO.
Telo Genomics Corp. is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions.
Telo Genomics Corp. was up 5.00 per cent, trading at $0.315 at 11:01 AM ET.
